Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer
- Conditions
- Advanced CancerMetastatic Cancer
- First Posted Date
- 2025-05-09
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Target Recruit Count
- 1000
- Registration Number
- NCT06963723
Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC
- First Posted Date
- 2023-04-04
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Target Recruit Count
- 178
- Registration Number
- NCT05798663
- Locations
- 🇺🇸
Kaiser Permanente Oakland Medical Center, Oakland, California, United States
🇺🇸Kaiser Permanente Roseville Medical Center, Roseville, California, United States
🇺🇸Kaiser Permanente San Francisco Medical Center, San Francisco, California, United States
Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2022-06-07
- Last Posted Date
- 2023-01-27
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Registration Number
- NCT05408026
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
- Conditions
- Endometrial Cancer
- Interventions
- First Posted Date
- 2020-07-24
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Target Recruit Count
- 148
- Registration Number
- NCT04486352
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸Medstar Georgetown Cancer Institute, Washington, District of Columbia, United States
Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide
- Conditions
- Hormone Sensitive Prostate CancerProstate Cancer MetastaticNon-metastatic Prostate CancerMetastatic Prostate CancerProstate CancerCastrate Resistant Prostate Cancer
- Interventions
- First Posted Date
- 2020-04-06
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Target Recruit Count
- 111
- Registration Number
- NCT04335682
- Locations
- 🇺🇸
University of California - San Francisco at Mount Zion, San Francisco, California, United States
🇺🇸Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer
- Conditions
- Stage IIIA Non-small Cell Lung CancerStage IIIB Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2019-08-20
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Target Recruit Count
- 38
- Registration Number
- NCT04062708
- Locations
- 🇺🇸
NorthWestern University, Chicago, Illinois, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM
- Conditions
- Myeloma, Multiple
- Interventions
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Target Recruit Count
- 79
- Registration Number
- NCT04009109
- Locations
- 🇺🇸
Northern Light Eastern Maine Medical Center, Bangor, Maine, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma in RelapseMultiple MyelomaRefractory Multiple Myeloma
- Interventions
- First Posted Date
- 2018-10-11
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Target Recruit Count
- 14
- Registration Number
- NCT03702725
- Locations
- 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease
- Conditions
- Rheumatoid ArthritisCrohn DiseaseMultiple SclerosisUlcerative ColitisAutoimmune DiseasesPsoriasisPolymyalgia RheumaticaSystemic Lupus ErythematosusNon-small Cell Lung CancerGiant Cell Arteritis
- Interventions
- First Posted Date
- 2018-09-04
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Target Recruit Count
- 7
- Registration Number
- NCT03656627
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸St. Joseph Mercy Hospital, Ann Arbor, Michigan, United States
Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma
- Conditions
- Mantle Cell LymphomaB Cell Lymphoma
- Interventions
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Target Recruit Count
- 39
- Registration Number
- NCT03478514
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸University of Maryland, Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States